Business Context and Reporting Period
Company: National Research Corporation (NRC Health)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: NRC Health provides subscription-based analytics and insights solutions to healthcare organizations, focusing on patient experience, employee engagement, reputation management, and governance. The company operates as a single reporting segment primarily within the United States.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $143,060 | $148,580 | $151,568 |
| Operating Income | $35,194 | $40,045 | $46,543 |
| Net Income | $24,783 | $30,971 | $31,800 |
| Operating Margin | 25% | 27% | 31% |
| Cash from Operating Activities | $34,625 | $38,113 | $36,265 |
| Recurring Contract Value (TRCV) | $133,218 | $141,855 | $146,839 |
| Total Debt Outstanding | $62,801 | $36,787 | N/A |
| Cash and Cash Equivalents | $4,233 | $6,653 | $25,026 |
Debt Structure (as of Dec 31, 2024):
- Term Loan: $14.3 million outstanding.
- Delayed Draw Term Loan: $48.5 million outstanding (with $24 million availability).
- Line of Credit: $0 outstanding (with $30 million availability).
- Interest Rate: Floating rate (SOFR + 235 bps), approximately 6.9% at year-end.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4% ($5.5 million) compared to 2023, primarily due to decreased recurring revenue from the existing client base. Non-core solutions accounted for 34% of this decrease.
- Margin Compression: Operating margin declined from 27% to 25% due to revenue declines while direct expenses and depreciation/amortization increased.
- Increased Interest Expense: Total other expense increased significantly due to higher interest costs ($1.7 million increase) from borrowings on the Line of Credit and Delayed Draw Term Loan, alongside lower interest income.
- Acquisition: Acquired Nobl Health in July 2024 for approximately $6.3 million (including contingent consideration) to expand rounding solutions. This added $4.5 million to goodwill.
- Capital Allocation: Repurchased 1.15 million shares for $30.8 million and paid $11.3 million in dividends during 2024.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- TRCV Trend: Total Recurring Contract Value (TRCV) declined for several quarters but increased slightly in Q4 2024. Management expects revenue growth to follow TRCV growth with a lag of a few quarters.
- Cost Initiatives: Workforce reductions in Q4 2024 are expected to lower fixed expenses in future periods. However, margins may face pressure from new CEO compensation.
- Leadership Transition: Trent Green was appointed CEO effective June 1, 2025. This transition includes an estimated $4.9 million signing bonus charge in Q2 2025 and quarterly non-cash equity charges of approximately $608,000.
- Capital Expenditures: Estimated $5.8 million in building renovation costs for 2025, funded by operating cash flows and borrowings.
Key Risks & Contingencies:
- Client Concentration: Top 10 clients accounted for 17% of 2024 revenue. Contracts are generally renewable annually and cancelable on short notice.
- Regulatory & Economic: Revenue is sensitive to healthcare industry consolidation, federal budget legislation (Medicare/Medicaid), and economic downturns affecting client budgets.
- Cybersecurity: The company faces risks from cyber-attacks, having experienced service suspensions in 2020 and 2022 due to third-party provider breaches (no data compromised).
- Working Capital: The company reported a working capital deficit of $16.3 million as of December 31, 2024, driven by large deferred revenue balances and debt obligations.
Investor Verification Checklist
- TRCV Recovery: Verify if the slight Q4 2024 increase in Total Recurring Contract Value sustains into 2025 to support revenue growth projections.
- CEO Compensation Impact: Monitor Q2 2025 financials for the $4.9 million signing bonus charge and subsequent quarterly equity charges for the new CEO.
- Debt Covenants: Confirm continued compliance with the fixed charge coverage ratio (1.10x) and cash flow leverage ratio (3.00x under old agreement; 3.50x under new Feb 2025 agreement).
- Client Retention: Assess retention rates given the 4% decrease in 2024 and the competitive landscape (Press Ganey, Qualtrics).
- Renovation Costs: Track the $5.8 million estimated 2025 capital expenditure for headquarters renovations against cash flow generation.